Anti‐tumour necrosis factor treatment of inflammatory bowel disease in liver transplant recipients

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Alimentary Pharmacology and Therapeutics

• Publication date

  2012-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1365-2036.2012.05217.xPMID 22779779
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis.

  2012cited by this paper
• The safety and efficacy of antitumour necrosis factor‐alpha therapy for inflammatory bowel disease in patients post liver transplantation: a case series

  2012cited by this paper
• Epstein-Barr virus infection

  2012cited by this paper
• Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis.

  2012cited by this paper
• Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters Committee

  2010cited by this paper
• Anti-Tumor Necrosis Factor Therapy for Inflammatory Bowel Disease in the Setting of Immunosuppression for Solid Organ Transplantation

  2010cited by this paper
• Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry

  2009cited by this paper
• Risk factors for recurrence of primary sclerosing cholangitis after liver transplantation

  2008cited by this paper
• Risk factors for recurrence of primary sclerosing cholangitis after liver transplantation

  2008cited by this paper
• Infliximab for ulcerative colitis following liver transplantation.

  2007cited by this paper
• Inflammatory Bowel Disease After Liver Transplantation: Risk Factors for Recurrence and De Novo Disease

  2006cited by this paper
• Infliximab for induction and maintenance therapy for ulcerative colitis.

  2005cited by this paper
• The clinical course of ulcerative colitis after orthotopic liver transplantation for primary sclerosing cholangitis: further appraisal of immunosuppression post transplantation

  2005cited by this paper
• Infliximab maintenance therapy for fistulizing Crohn's disease.

  2004cited by this paper
• Maintenance infliximab for Crohn's disease

  2002cited by this paper
• Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.

  2002cited by this paper
• Management of Crohn's disease in adults

  2001cited by this paper
• Management of Crohn's Disease in Adults

  2001cited by this paper
• Epstein-Barr virus infection.

  2000cited by this paper
• Recurrence of primary sclerosing cholangitis following liver transplantation

  1999cited by this paper
• Ulcerative colitis has an aggressive course after orthotopic liver transplantation for primary sclerosing cholangitis

  1998cited by this paper
• Inflammatory bowel disease in primary sclerosing cholangitis: An analysis of patients undergoing liver transplantation

  1995cited by this paper
• Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis.

  1992cited by this paper
• Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis.

  1991cited by this paper
• For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group

  year unknowncited by this paper

• De novo Inflammatory Bowel Disease following Liver and Heart Transplantation: A Case Series Exploring the Role of IL-23 Pathway-Targeted Therapy

  2025cites this paper
• Infections in primary sclerosing cholangitis and inflammatory bowel disease: a systematic review and meta-analysis

  2025cites this paper
• The Use of Immunomodulators, Biologic Therapies, and Small Molecules in Patients With Inflammatory Bowel Disease and Solid Organ Transplant

  2024cites this paper
• Primary sclerosing cholangitis and inflammatory bowel disease: a complicated yet unique relationship.

  2024cites this paper
• Liver Transplantation for Primary Sclerosing Cholangitis (PSC) With or Without Inflammatory Bowel Disease (IBD)—A European Society of Organ Transplantation (ESOT) Consensus Statement

  2023cites this paper
• Safety of Biologic and Small Molecule Therapy for Inflammatory Bowel Disease Among Solid Organ Transplant Recipients: Systematic Review and Meta-Analysis.

  2023cites this paper
• Concurrent inflammatory bowel disease and primary sclerosing cholangitis: a review of pre- and post-transplant outcomes and treatment options

  2023cites this paper
• Use of IBD Drugs in Patients With Hepatobiliary Comorbidities: Tips and Tricks.

  2022cites this paper
• The use of non‐transplant biologics in solid organ transplant recipients: A practical review for the frontline clinician

  2022cites this paper
• Safety of biologic treatments in solid organ transplant recipients: A systematic review.

  2021cites this paper
• Safety and Efficacy of Ustekinumab for Ulcerative Colitis in a Liver Transplant Patient.

  2021cites this paper
• Ustekinumab is a safe and effective biologic agent for Crohn's disease in a Liver Transplant patient.

  2020cites this paper
• Use of Tofacitinib for ulcerative colitis in a liver transplant patient.

  2020cites this paper
• The Course of Ulcerative Colitis After Pediatric Liver Transplantation for Sclerosing Cholangitis.

  2020cites this paper
• Liver Surgery in Patients With Inflammatory Bowel Disease

  2019cites this paper
• Safety of Combination Biologic and Antirejection Therapy Post-Liver Transplantation in Patients With Inflammatory Bowel Disease.

  2019cites this paper
• Unique Phenotypic Characteristics and Clinical Course in Patients With Ulcerative Colitis and Primary Sclerosing Cholangitis: A Multicenter US Experience.

  2019cites this paper
• Specific Features of Patients With Inflammatory Bowel Disease and Primary Sclerosing Cholangitis

  2019cites this paper
• Tumor Necrosis Factor Alpha Inhibition for Inflammatory Bowel Disease after Liver Transplant for Primary Sclerosing Cholangitis

  2018cites this paper
• Harmful Effects and Potential Benefits of Anti-Tumor Necrosis Factor (TNF)-α on the Liver

  2018influential citation
• Management of Tumor Necrosis Factor α Inhibitor Therapy After Renal Transplantation: A Comparative Analysis and Associated Outcomes

  2018cites this paper
• Efficacy and Safety of Anti-TNF-α Agents in Inflammatory Bowel Disease After Liver Transplant: A Case Series.

  2018cites this paper
• Natural History of Established and De Novo Inflammatory Bowel Disease After Liver Transplantation for Primary Sclerosing Cholangitis

  2018cites this paper
• The Gastroenterologist's Guide to Management of the Post‐Liver Transplant Patient

  2018cites this paper
• Anti-TNF&agr; Treatment in Children and Adolescents With Combined Inflammatory Bowel Disease and Autoimmune Liver Disease

  2018cites this paper
• Effectiveness and safety of anti-TNF therapy for inflammatory bowel disease in liver transplant recipients for primary sclerosing cholangitis: A nationwide case series.

  2018cites this paper
• Efficacy and safety of vedolizumab as a treatment option for moderate to severe refractory ulcerative colitis in two patients after liver transplant due to primary sclerosing cholangitis.

  2017cites this paper
• Hepatic Issues and Complications Associated With Inflammatory Bowel Disease: A Clinical Report From the NASPGHAN Inflammatory Bowel Disease and Hepatology Committees.

  2017cites this paper
• Complete Regression of Psoriatic Arthritis After Belatacept Conversion in a Highly HLA‐Sensitized Kidney Transplant Patient

  2017cites this paper
• Inflammatory bowel disease in liver transplanted patients

  2017cites this paper
• The Care of the Postliver Transplant Patient

  2017cites this paper
• Vedolizumab is safe and effective in moderate‐to‐severe inflammatory bowel disease following liver transplantation

  2017cites this paper
• Timing, Management, and Outcomes of Liver Transplantation in Primary Sclerosing Cholangitis

  2017cites this paper
• Cholestatic Liver Diseases After Liver Transplant.

  2017cites this paper
• Safety and Efficacy of Biologic Agents for the Management of Inflammatory Bowel Disease After Liver Transplantation

  2017cites this paper
• Universal Microfluidic System for Analysis and Control of Cell Dynamics

  2017cites this paper
• Primary Sclerosing Cholangitis-Associated Inflammatory Bowel Disease

  2017cites this paper
• Eficacia y seguridad de vedolizumab como opción terapéutica en colitis ulcerosa moderada-grave refractaria en dos pacientes trasplantados hepáticos por colangitis esclerosante primaria

  2017cites this paper
• S2k Leitlinie Autoimmune Lebererkrankungen

  2017influential citation
• Safety of Anti-TNF Treatment in Liver Transplant Recipients: A Systematic Review and Meta-analysis

  2017cites this paper
• [Practice guideline autoimmune liver diseases - AWMF-Reg. No. 021-27].

  2017influential citation
• Interactions between primary sclerosing cholangitis and inflammatory bowel disease: implications in the adult liver transplant setting

  2017cites this paper
• Evaluation and Treatment of Acute and Subacute Hearing Loss: A Review of Pharmacotherapy

  2017cites this paper
• Letter: vedolizumab for the management of inflammatory bowel disease in patients after liver transplantation for primary sclerosing cholangitis

  2017cites this paper
• Management of Ulcerative Colitis Using Vedolizumab After Liver Transplantation for Primary Sclerosing Cholangitis.

  2016cites this paper
• Evolving strategies to reduce colectomy rates in primary sclerosing cholangitis-inflammatory bowel disease: clinical remission of corticosteroid refractory colitis post-liver transplant with vedolizumab

  2016cites this paper
• Anti-TNFα therapy for chronic inflammatory disease in kidney transplant recipients

  2016cites this paper
• [A case of de novo inflammatory bowel disease after liver transplantation for cryptogenic cirrhosis].

  2016cites this paper
• A case of de novo inflammatory bowel disease after liver transplantation for cryptogenic cirrhosis

  2016cites this paper
• Solid Organ Transplantation in Patients with Inflammatory Bowel Diseases (IBD): Analysis of Transplantation Outcome and IBD Activity in a Large Single Center Cohort

  2015cites this paper
• Primary sclerosing cholangitis associated with inflammatory bowel disease: an update

  2015cites this paper
• Ustekinumab is effective and safe in the treatment of Crohn's disease refractory to anti-TNFα in an orthotopic liver transplant patient.

  2015cites this paper
• Antitumor necrosis α treatment in primary sclerosing cholangitis associated inflammatory bowel disease after liver transplantation

  2015cites this paper
• Management of ulcerative colitis pre- and post-liver transplant for primary sclerosing cholangitis: two case reports and review of literature

  2014cites this paper
• Clinical management of inflammatory bowel disease in the organ recipient.

  2014cites this paper
• Letter: infliximab therapy in inflammatory bowel disease patients after liver transplantation

  2013cites this paper
• Tumour necrosis factor‐α inhibitor use in patients with psoriasis with organ transplantation

  2013cites this paper
• Primary Sclerosing Cholangitis: Current and Future Management Strategies

  2013cites this paper
• Inflammatory Bowel Disease after Liver Transplantation for Primary Sclerosing Cholangitis

  2013cites this paper
• Topical glycopyrrolate for axillary hyperhidrosis

  2013cites this paper
• Long-Term Management of the Liver Transplant Patient

  2011cites this paper